期刊文献+

抗CD28单抗和IL-15对CIK增殖和杀肿瘤作用的研究 被引量:3

Study of anti-CD28 antibody and IL-15 on proliferation and anti-tumor activity of CIK
原文传递
导出
摘要 CIK是肿瘤过继性细胞免疫治疗中的免疫效应细胞。为使CIK在实验室里能被更有效地诱导增殖并赋予其更强的杀肿瘤效应,我们在CIK常规培养环境中加入抗CD28单抗和IL-15,探讨抗CD28单抗和IL-15对CIK增殖和杀肿瘤效应。取人外周血单个核细胞(PBMC),预先以常规方法诱导CIK,然后加入抗CD28单抗和IL-15与CIK共培养。用全自动五分类血液分析仪计数CIK增殖率;用流式细胞术测定CIK中粒酶B、穿孔素和CD107a等分子的表达率;用ELISA方法检测CIK分泌IL-10、IL-12、INF-γ和TNF-α水平;用乳酸脱氢酶释放法测定CIK对人肺癌细胞株(A549)、乳腺腺癌细胞株(MFC-7)和人黑素瘤细胞株(HME1)的杀伤活性。PBMC经常规CIK诱导培养以后再加入抗CD28单抗和IL-15与对照组比较,前者细胞增殖率明显增强(P<0.05);在CIK培养体系中加入抗CD28单抗和IL-15可促进颗粒酶B、穿孔素和CD107a等分子的表达率进一步增强(P<0.05);加入抗CD28单抗和IL-15,培养8d后CIK对A549、MFC-7和HME1细胞杀伤活性分别为82.2%、59.3%和70.6%,与对照组(分别为60.9%、49.6%和48.4%)相比差异有统计学意义(P<0.05);在培养体系中加入抗CD28单抗和IL-15,培养8d后其细胞因子IFN-γ、TNF-α分泌水平显著高于对照组(P<0.05),组间IL-10和IL-12的分泌量未见显著差异(P>0.05)。实验说明在CIK培养体系中加入抗CD28单抗和IL-15可增加CIK增殖率并提高其抗肿瘤效应。 CIKs are immune effector cells in cell biological cancer therapy. To improve effectively the capacity of inducing proliferation and anti-tumor activity of CIK in the lab, we added anti-CD28 antibody and IL-15 into the culture system, discussing anti-CD28 antibody and IL-15 on proliferation and anti-tumor effect of CIK. CIK was first cultured from peripheral blood mononuclear cell (PBMC) and then co-cultured with anti-CD28 antibody and IL-15. The proliferation rate of CIK was counted by fully automatic five categories of blood analyzer. The expressions of granzyme B, perforin, CD107a were detected by flow cytometry. Cytokines of IL-10, IL-12, INF-γand TNF-α were quantified by ELISA. Cytotoxicities of CIK on lung cancer cell line (A549), breast adenocarcinoma cell line (MFC-7) and human melanoma cell line (HME1) were measured by lactate dehy- drogenase releasing assay. Adding anti-CD28 antibody and IL-15 into CIK conventional culture system could significantly increase proliferation rate and promote expression of granzyme B, perforin, and CD107a(P〈0.05). The anti-tumor activity of CIK on 8 day after adding anti-CD28 antibody and IL-15 on A549, MFC-7 and HME1 were 82.2%, 59.3%, and 70.6M respectively, it was significantly different from control group(60.9 %, 49.6 % and 48.4 % ) (P〈0.05). The secretion levels of IFN-γand TNF-α after co-culutre were also significantly higher than those in the control group(P〈0.05), but there was no difference of IL-10 and IL-12 secretion levels between each group(P〉0.05). This study demonstrated that adding anti-CD28 antibody and IL-15 into CIK conventional culture system could enhance CIK proliferation and anti-tumor activity.
出处 《现代免疫学》 CAS CSCD 北大核心 2012年第6期484-489,共6页 Current Immunology
基金 南京军区医学科技创新课题(11MA040)
关键词 抗CD28单抗 IL-15 CIK 增殖 抗肿瘤活性 anti-CD28 antibody IL-15 CIK proliferation anti-tumor activity
  • 相关文献

参考文献26

  • 1Schmidt W, Negrin RS, Kiem HP, et al . Use of a SCID mouse/human lymphoma model to evaluate cytokine-induced killer ceils with potent antitumor cell activity [J]. J Exp Med, 1991,174:139-149.
  • 2秦福丽,张绍林,孙慧,张秋堂,席雨人.PHA对CIK细胞增殖和免疫表型影响的研究[J].现代免疫学,2005,25(5):421-422. 被引量:5
  • 3Chong AS, Aleksijevie A, Scuderi P, et al. Phenotypic and functional analysis of lymphokine-activated killer (LAK) cell clones. Ability of CD3+, LAK cell clones to produce inter- feron-gamma and tumor necrosis factor upon stimulation with tumor targets[J]. Cancer Immunol Immunother . 1989, 29 : 270-278.
  • 4黄朝晖,华东,王丰,李莉华,王金福.人外周血细胞因子诱导的自然杀伤细胞的体外高效扩增[J].现代免疫学,2004,24(5):395-398. 被引量:4
  • 5Huntington ND, Alves NL, Legrand NI, et al. IL-15 transpre- sentation promotes both human T-cell reconstitution and T-cell-dependent antibody responses in vivo[J]. Proc Natl AcadSciUSA. 2011,108: 6217-6222.
  • 6Prakash MD, Bird CH, Bird PI. Active and xymogen forms of granzyme B are constitutively released from cytotoxic lym- phocytes in the absence of target cell engagement[J]. Immu- nol Cell Biol, 2009, 87:249-254.
  • 7Aktas E, Kucuksezer UC, Bilgic S, et al. Relationship be- tween CD107a expression and cytotoxic activity[J]. Cell Im- munol, 2009,254 : 149-154.
  • 8刘军权 韩慧敏 陈复兴.用乳酸脱氢酶试剂盒检测LAK细胞活性.临床医学检验,1995,13(2):83-83.
  • 9陈复兴 刘军权 许祥裕 等.人CD3单克隆抗体体外诱导T淋巴细胞和肿瘤浸润性淋巴细胞增殖的研究.南京部队医药,1994,5:15-18.
  • 10Fagerli UM, Ullrich K, Stiihmer T, etal. Serum/glucoeor- ticoid-regulated kinase 1 (SGK1) is a prominent target gene of the transcriptional response to cytokines in multiple myelo- ma and supports the growth of myeloma cells[J]. Oncogene, 2011, 30:3198-3206.

二级参考文献53

  • 1丁军颖,王润田.人MICA基因多态性和表达特性与肿瘤的关系[J].现代免疫学,2007,27(2):165-168. 被引量:10
  • 2[1]Herberman RB. Cancer immunotherapy with natural killer cells[J]. Semin Oncol,2002,29(3 suppl 7):27.
  • 3[2]Carlens S,Gilljam M,Chambers BJ,et al. A new method for in vitro expansion of cytotoxic human CD3-CD56+ natural killer cells[J]. Hum Immunol,2001,62:1092.
  • 4[3]Escudier B,Farace F,Angevin E,et al. Immunotheraphy with interleukin-2 (IL-2) and lymphokine-activated natural killer cells:improvement of clinical responses in metastatic renal cell carcinoma patients previously treated with IL-2[J]. Eur J Cancer,1994,30A:41078.
  • 5[4]Pierson BA,Europa AF,Hu WS,et al. Production of human natural killer cells for adoptive immunotheraphy using a computer-controlled stirred-tank bioreactor[J]. J Hematother,1996,5:475.
  • 6[5]Luhm J, Brand JM,Koritke P,et al. Large-scale generation of natural killer lymphocytes for clinical application[J]. J Hematother Stem Cell Res,2002,11:651.
  • 7[6]Vitolo D, Vujanovic NL, Rabinowich H, et al. Rapid IL-2=induced adherence of human natural killer cells. Expression of mRNA for cytokines and IL-2 receptors in adherent NK cells[J]. J Immunol, 1993,151:1926.
  • 8Dunn GP, Bruce AT, Iked AH, et al. Cancer immunoediting: from immunosurveillance to tumor escape [ J ]. Nat Immunol, 2002, 3 (11) : 991 -998.
  • 9Kacani L, Wurm M, Schennach H, et al. Immunosuppressive effects of soluble factors serected by head and neck squamous cell carcinoma on dendritic cells and T lymphocytes[ J]. Oral Oncol, 2003, 39(7) : 672 - 679.
  • 10Busche A, Goldmann T, Naumannu, et al. Natural killer cell-mediated rejection of experimental human lung cancer by genetic overexpression of major histocompatibility complex class I chain-related gene A [J]. Hum Gene Ther, 2006, 17(2) : 135 -146.

共引文献61

同被引文献17

  • 1YongliangZhang,ChenDong.MAP Kinases in Immune Responses[J].Cellular & Molecular Immunology,2005,2(1):20-27. 被引量:20
  • 2Eva Rettinger, Andreas Glatthaar, Behnaz, et al.SMAC Mi- metic BV6 Enables Sensitization of Resistant Tumor Cells but also Affects Cytokine-Induced Killer (CIK) Cells: A Potential Challenge for Combination Therapy [ J ]. Front Pediatr,2014(2) :75.
  • 3Soeinski MA.Muhitargeted receptor tyrosine kinase inhibi- tion: Anantiangiogenic strategy in non- small cell lung cancer[ J ]. Cancer Treat Rev, 2011,6 ( 3 ) : 163-175.
  • 4Schmidt W, Negrin RS, Kiem HP, et al. Use of a SCID mouse/human lymphoma model to evaluate cytokine-in- duced killer cells with potent antitumor cell activity[ J] .J Exp Med, 1991 (174) : 139-149.
  • 5Chunsheng Liu, Lukkana Suksanpaisan, Yun-Wen, et al. Enhancing Cytokine Induced Killer Cell Therapy of Multi- ple Myeloma Exp Hematol[ J] .2013,41 (6) :508-517.
  • 6Andreas A Hombach, Gunter Rappl, Hinrich Abken. Ar- ming Cytokine-induced Killer Ceils With Chimeric Anti- gen Receptors: CD28 Outperforms Combined CD28- OX40 " Super - stimulation" [ J ]. Mol Ther, 2013, 21 (12) :2268-2277.
  • 7Motzer RJ,Bacik J, Murphy BA,et al.Interferon-alfa as a comparative treatment for clinical trials of new therapies against advanced renal cell carcinoma [ J ] .J Clin Oncol, 2004(20) :289-296.
  • 8Heng DY,Chi KN, Murray N, et al.A population-based study evaluating the impact of sunitinib on overall survival in the treatment of patients with metastatic renal cell cancer [ J ]. Cancer, 2009,11 (5) : 776 - 783.
  • 9Ferris RL, Whiteside TL, Ferrone S. Immune escape asso- ciated with functional defects in antigen-processing ma- chinery in head and neck cancer [ J ]. Clin Cancer Res, 2006,12(13) :3 890-3 895.
  • 10黄凯,杨新波,黄正明,耿淼,陈红艳,王建华,杨解人.金丝桃苷对正常小鼠免疫功能的影响[J].解放军药学学报,2009,25(2):133-135. 被引量:20

引证文献3

二级引证文献6

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部